(Q56892297)

English

Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

based on heuristic

inferred from title

Ursula Dietrich

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Mingkui Zhou

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Ioanna Kostoula

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Boris Brill

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Eugenia Panou

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Maria Sakarellos-Daitsiotis

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

0 references

publication date

23 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

number of pages

6

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1911-1916

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Passive immunization with human neutralizing monoclonal antibodies against HIV-1 in macaque models: experimental approaches.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

The role of antibodies in HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

AIDS/HIV. A boost for HIV vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Broad neutralization coverage of HIV by multiple highly potent antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

HIV vaccine development--improving on natural immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

A palmitoyl-tailed sequential oligopeptide carrier for engineering immunogenic conjugates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Synthetic carriers: sequential oligopeptide carriers SOCn-I and SOCn-II as an innovative and multifunctional approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Sequential oligopeptide carriers, SOCn, as scaffolds for the reconstitution of antigenic proteins: applications in solid phase immunoassays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Influenza virus H5N1 hemagglutinin (HA) T-cell epitope conjugates: design, synthesis and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Cross-clade neutralizing antibodies against HIV-1 induced in rabbits by focusing the immune response on a neutralizing epitope.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

A synthetic peptide-based polyoxime vaccine construct of high purity and activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Unprotected peptides as building blocks for branched peptides and peptide dendrimers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

The maltose-binding protein as a scaffold for monovalent display of peptides derived from phage libraries

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Measuring HIV neutralization in a luciferase reporter gene assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Artificial carriers: a strategy for constructing antigenic/immunogenic conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Humoral immunogenicity of an HIV-1 envelope residue 649-684 membrane-proximal region peptide fused to the plague antigen F1-V.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2012.01.026

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22269872%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56892297&oldid=1833388586"